AMENDMENTS TO THE CLAIMS:

1-13. (Cancelled)

14. (Withdrawn-currently amended) A method for immunotherapy comprising the step of administering to a subject in need of such immunotherapy the pharmaceutical composition according to claim 25 or 28.

15. (Cancelled)

16. (Withdrawn) The method according to claim 14, wherein said immunotherapy is a therapy against acute transplant rejections.

17. (Withdrawn-currently amended) A method for gene therapy comprising the step of administering to a subject in need of such gene therapy the pharmaceutical composition according to claim 25 or 28.

18-24. (Cancelled)

25. (Currently amended) A pharmaceutical composition comprising: ~~the bivalent diabody of claim 21~~

(i) a bivalent diabody comprising a non-covalent dimer of single chain F_V antibodies each consisting essentially of a V_H domain and a V_L domain specific to human CD3, wherein the V_H domain and the V_L domain are covalently linked either without a linker or via a peptide linker; the bivalent diabody is characterized by the following features:

(a) it is devoid of constant antibody domains;

(b) it specifically binds to human TCR/CD3 complex bivalently; and

(c) it is capable of suppressing an immune reaction; and

(ii) a suitable pharmaceutical carrier selected from the group consisting of an emulsion, a wetting agent and a sterile solution.

26. (Cancelled)

27. (Currently amended) The pharmaceutical composition of claim ~~26~~ 25, wherein the composition is a sterile solution.

28. (New) A pharmaceutical composition comprising:

(i) a bivalent diabody consisting essentially of a non-covalent dimer with two V_H and two V_L domains specific to human CD3, wherein each V_H-V_L pair is separated by a peptide linker or bound by a peptide bound characterized by the following features:

(a) it is devoid of constant antibody domains;

(b) it specifically binds to human TCR/CD3 complex;

(c) it is capable of suppressing an immune reaction; and

(d) it does not posses T cell activating properties in a peripheral blood mononuclear cell (PBMC) culture; and

(ii) a pharmaceutical carrier selected from the group consisting of an emulsion, a wetting agent and a sterile solution.

29. (New) The pharmaceutical composition of claim 25 or 28, wherein the V_H domain and the V_L domain of the bivalent diabody are covalently linked via a peptide linker SAKTTP (SEQ ID NO:1).

30. (New) The pharmaceutical composition of claim 25 or 28, wherein the V_H and the V_L domains of the bivalent diabody correspond to the variable domains of an antibody produced by the hybridoma of ATCC deposit number CRL 8001.

31. (New) The pharmaceutical composition of claim 30, wherein a cysteine at position H100A of the antibody produced by the hybridoma of ATCC deposit number CRL 8001 according to the Kabat numbering system has been exchanged for a serine.